Trial · NCT07354620
A Pilot Study on Reverse Aging (The REVERSE Study)
NCT07354620, Early phase 1, Active not recruiting, The Christ Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Pilot Study on Reverse Aging (The REVERSE Study). Trials, record NCT07354620. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07354620
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Pilot Study on Reverse Aging (The REVERSE Study)
- NCT number
- NCT07354620
- Status
- Active not recruiting
- Phases
- Early phase 1
- Enrollment
- 52 participants, actual
- Lead sponsor
- The Christ Hospital
- Conditions
- Aging
- Interventions
- Rapamycin (Tablets), Prolon diet
- First posted
- 2026-01-21
- Last updated
- 2026-01-21
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Biological Age from Baseline to End of Study based on Tru Diagnostic Tru Age OMICm Age test results. | 24 weeks | To evaluate the gradated effects of mTOR inhibition on a new OMIC methylation test that evaluates biological (vs chronological) age over a six-month period. |
| Secondary | To evaluate the effects of AMPK (AMP Kinase inhibition) on aging. Change in OMICm methylation from baseline to Week 24 based on Tru Diagnostic Tru Age OMICm Age test results. | 24 weeks | . This will duplicate studies already done utilizing a 5 day Fasting Mimicking Diet (FMD) (Prolon) on aging. The FMD diet will be administered 6 times - at monthly intervals. Change in OMICm methylation from baseline to Week 24 |
| Secondary | Effect of weekly low-dose rapamycin on aging based on Tru Diagnostic Tru Age OMICm Age test results. | 24 weeks | Change in OMICm methylation from baseline to Week 24 |
| Secondary | Lowering of insulin resistance based on Tru Diagnostic Tru Age OMICm Age test results. | 24 weeks | To evaluate the combined effects of AMPK and low-dose weekly rapamycin, at lowering insulin resistance, and thereby PI3K (PI3 kinase). |
| Secondary | Effects on insulin resistance | 24 weeks | To stratify outcomes of the prior three outcomes based on insulin resistance. This will be monitored using a Quest Lab Insulin Resistance panel to determine if insulin resistance is a confounding variable from any of the above. Variability of results in a, b, or c based on high, low or moderate insulin resistance. |
| Secondary | Does reversal of age improve cognition based on the Cognitive Flexibility Inventory. | 24 weeks | Changes in the Cognitive Flexibility Inventory from baseline to week 24. Scores range from 20-140, with a higher score representing a better outcome. |
| Secondary | Patterns based on Age based on Tru Diagnostic Tru Age OMICm Age test results. | 24 weeks | To see if any pattern exists within age group categories. (50-65; older than age 65). Change in OMICm methylation results from baseline to Week 24 by two sub populations: ages 50-65 and ages older than age 65 |
| Secondary | Sex Difference based on Tru Diagnostic Tru Age OMICm Age test results. | 24 weeks | Change in OMICm methylation from baseline to Week 24 by male vs female |
| Secondary | Safety and tolerability of rapamycin and Prolon | 28 weeks | Review of adverse reactions from baseline to Week 28 |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07354620
GET https://conductscience.org/api/trials/v1/NCT07354620/registered